1 |
ClinicalTrials.gov (NCT00270517) Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia. U.S. National Institutes of Health.
|
2 |
EDP-420, a Bicyclolide (Bridged Bicyclic Macrolide), Is Active against Mycobacterium avium. Antimicrob Agents Chemother. 2007 May; 51(5): 1666-1670.
|
3 |
Company report (JMI Laboratories)
|
4 |
Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol. 2004 Dec;54(5):1287-94.
|
5 |
The fused TrpEG from Streptomyces venezuelae is an anthranilate synthase, not a 2-amino-2-deoxyisochorismate [corrected] (ADIC) synthase. Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-9-13.
|
6 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
|
7 |
Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23.
|
8 |
The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
|
9 |
Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
|
10 |
How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
|
11 |
Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA. 1999 Jul;5(7):939-46.
|
|
|
|
|
|
|